Skip to content

Released Aug 12, 2025, before the open

10-Q filed Aug 12, 2025, 43 days after period end · 0001576885-25-000093

Q2 2025 · 10-Q
Revenue—
Net Income-$40.95MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.68N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$41,750,000N/M
Operating Cash Flowderived-$31,832,000N/M
Free Cash Flowderived-$31,841,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Net Income-$40.95M-$20.54M-$11.61M-$10.15M
EPS Diluted-$0.68-$0.34-$0.28-$0.25

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR